BiotechTube

Foralumab

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Progressive Multiple Sclerosis

Conditions

Secondary Progressive Multiple Sclerosis

Trial Timeline

Nov 15, 2023 → Nov 1, 2025

NCT ID
NCT06292923

About Foralumab

Foralumab is a phase 2 stage product being developed by Tiziana Life Sciences for Secondary Progressive Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06292923. Target conditions include Secondary Progressive Multiple Sclerosis.

What happened to similar drugs?

6 of 20 similar drugs in Secondary Progressive Multiple Sclerosis were approved

Approved (6) Terminated (0) Active (14)
🔄KHK7580Kyowa KirinPhase 3
🔄KHK7580Kyowa KirinPhase 3
✅Cinacalcet HClKyowa KirinApproved
🔄KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
🔄paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06292923Phase 2Recruiting
NCT05028946Phase 1Withdrawn
NCT04983446Phase 2Withdrawn

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43